Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
iPRRT trial: what clinicians have said so far
Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer
- NCT05583708 ↗
- Recruiting
- Weill Medical College of Cornell University
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on iPRRT (lutetium lu 177 dotatate plus pembrolizumab in Merkel cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on iPRRT so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 4 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Single Arm Study With Safety Run-in of Peptide Receptor Radionuclide Therapy (PRRT) in Combination With Immunotherapy for Patients With Merkel Cell Cancer (HCRN MCC20-443; iPRRT Study)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Merkel Cell Carcinoma
- Interventions
- Pembrolizumab; Lutetium Lu 177 dotatate
- Arms
- Experimental: Pembrolizumab + Lutetium Lu177 · Experimental
- Enrollment
- 18 (estimated)
- Primary outcomes
- Objective Response Rate (ORR)
- Sponsor
- Weill Medical College of Cornell University with Hoosier Cancer Research Network
- Start
- Aug 3, 2023
- Primary completion
- Dec 2028 (estimated)
- Results posted
- No
- Registry record
- NCT05583708 · updated Sep 25, 2026